EMA Recommends Granting a Conditional Marketing Authorisation for Linvoseltamab By Ogkologos - April 10, 2025 409 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed and refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Single Dose of HPV Vaccine Yields Long-Term Protection from Many Cancer-Causing... April 10, 2020 Sacituzumab Govitecan Plus Pembrolizumab Demonstrate Encouraging Activity in Patients with mUC... February 5, 2024 FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive,... November 20, 2024 Por qué no voy a “superar” los efectos a largo plazo... July 20, 2021 Load more HOT NEWS ctDNA Detection After Initial Treatment of Early-Stage NSCLC Has Potential to... Final DFS Analysis Demonstrates that Adjuvant Osimertinib Improves DFS in Patients... Similarity of Molecular Portraits in Synchronous Bilateral Breast Cancers Could be... Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not...
